If you would be willing to participate in a short survey about treatment for Small Cell Lung Cancer, please let me know!🚨 Attention Healthcare Professionals! 🚨With the recent approval of the first Bispecific T-Cell Engager (Bispecifics) and its inclusion in the NCCN Guidelines as a novel therapy for ES-Small Cell Lung Cancer (ES-SCLC), we’re excited to launch a quality improvement initiative at GO2 for Lung Cancer! We need YOUR input! This quick 10-minute survey seeks to:
🩺 Understand real-world implementation experiences.
💡 Identify opportunities to support the lung cancer community.
🛡️ Gather insights on preparation for managing potential side effects, like cytokine release syndrome.Your expertise matters! Whether you’re an MD, RN, RPh, ARNP, MSW, PAc, or another healthcare professional, your feedback will help improve access to innovative treatments and survival outcomes for people living with ES-SCLC.Help us broaden the impact! Please share this survey with colleagues across healthcare systems—urban, rural, and HPSAs alike.Have questions? Reach out anytime at BEREADI@go2.org. Thank you for being part of this critical initiative! #LungCancerCare #Bispecifics #ESSCLC #HealthcareInnovation #QualityImprovement